REGISTRATION INSTRUCTIONS & RIQAS POLICIES

CRITERIA FOR PARTICIPATION

This programme is available to any laboratory routinely involved in the identification and susceptibility testing of the microbes listed in this document.

INTRODUCTION

Method questionnaires are available for all routine RIQAS Programmes and are reviewed and updated every month, as indicated by the issue date at the bottom of every page. They are designed to allow you to register for this RIQAS Programme and to inform you of RIQAS protocols and policies. It is important that you read and understand all the information in these introductory pages before completing the enrolment document, which forms the basis of your registration and contract with RIQAS. If you have any questions or concerns about any of the information presented in this document, please contact RIQAS either directly or through your local Randox Laboratories representative. RIQAS Calendar dates and information about the RIQAS portfolio of products can be found at www.randox.com/external-quality-assessment.

REGISTRATION INSTRUCTIONS

NOTE: IF A REGISTERED PARTICIPANT DOES NOT PARTICIPATE FOR A CYCLE, THEY WILL BE EXPECTED TO COMPLETE NEW ENROLMENT DOCUMENTS IN ORDER TO RE-JOIN THE PROGRAMME.

METHOD QUESTIONNAIRE:- To be retained by participant

This method questionnaire should be completed and retained by you for your records. Please ensure that you complete the method questionnaire in full. Your details will help us to classify your results correctly and thus provide you with useful statistical data.

Following this introduction section is the method questionnaire which indicates the method for identification, Guidelines and antibiotics available. On the method questionnaire, state your method for identification and Guideline that you use in your laboratory. If codes are not available for your method or guideline, please state the details clearly in the section at the end of the enrolment document. If you use any antibiotics that are not listed in the method questionnaire please also state these clearly at the end of the enrolment document. Please do not use Brand names.

The guidelines referred to above are in relation to antimicrobial susceptibility testing. If unsure please contact RIQAS.

Once your method questionnaire has been completed, you must transfer the information onto your enrolment document.

ENROLMENT DOCUMENT:- To be returned to RIQAS

Please be aware that it may take up to 3 weeks to process enrolment documents if you are not entering your own assay details. When registering RIQAS enrolment documents, it is recommended that you state business contact details, rather than personal.

A. LABORATORY REFERENCE NUMBER

On receipt of an enrolment document, each participant is assigned a laboratory reference number which consists of a participant number which is unique to your laboratory and a registration letter which is assigned for each new registration we receive from you. If you are a current or previous participant, please state your participant number on the enrolment document. If you do not have a Laboratory Reference Number, this will be generated by RIQAS when you register for the first time. Please quote this number on all correspondence with RIQAS.

B. CYCLE/PRODUCT REQUIREMENTS

Please tick the cycles you wish to subscribe for. If there is more than one kit/product offered for the programme, please also tick the kit you wish to subscribe for.

C. PRIMARY CONTACT DETAILS

It is important to state the full address details of the Quality Assessment Officer or contact person who will receive all correspondence during the cycle. Please also state the company name of the Randox representative who is supplying you with the RIQAS product under ‘Randox Office/Distributor’

Please inform RIQAS of any change to contact details as soon as possible.

D. RIQASNet

RIQASnet is a web-based online method for result entry / viewing of released reports. To access RIQASnet go to www.riqas.net. Internet access and login details are required for RIQASnet and Adobe Reader is required for viewing reports. Your initial login information and password will be supplied by RIQAS. Once you have logged in for the first time you will be able to change your RIQASNet password. If you forget your password please follow the ‘Forgotten Password’ link. Your login information will be based on the 1st email address you supply on your enrolment document. A PDF copy of the report will be sent to this address and can also be sent to 2 other email addresses. These addresses should be stated on your enrolment document.

E. PDF REPORTS

Reports are sent as PDF files. These files can be sent to up to 3 email addresses. Adobe Reader is required to view the reports. The email addresses to which reports are sent can be reviewed and changed on RIQASnet.

F. CUSTOMER DECLARATION

The declaration indicates that by submitting your enrolment document to RIQAS, either directly or via your local Randox representative, you have read and understood the RIQAS policies stated in the most recent Method Questionnaire associated with this programme. You understand that the submission of your enrolment document to RIQAS marks the beginning of an on-going agreement, and you will be automatically enrolled in subsequent cycles of this programme until we receive written confirmation of your cancellation. This should be received 12 weeks prior to the month in which the cycle starts. You understand that you must inform RIQAS of any changes to your contact details, assay details or contract status. You authorise Randox Laboratories Ltd. to send communication related to the products and service provided to the e-mail or postal addresses stated on your submitted enrolment document. You understand that you are permitted to request disclosure of, change or erase personal details held by Randox Laboratories Ltd. at any time. Note: Method questionnaires are updated every month and the issue date is stated on every questionnaire and enrolment document.
G. REGISTRATION OF ASSAY DETAILS
Labs can register their assay details using the ‘Registration of Assay Details’ section of the enrolment document. Once a participant has registered they will receive an email containing their RIQASNet login information. Once you have successfully logged in to RIQASNet you will see your various laboratory reference numbers for each registered programme.

If no method/guideline is available in the method questionnaire for your test, please state the details clearly in the section at the end of the enrolment document.

ONCE COMPLETED, THE ENROLMENT DOCUMENT SHOULD BE SENT TO RIQAS FOR REGISTRATION.

H. UPDATING ASSAY DETAILS
It is possible to change your method and Guideline during a cycle. Please email mail@riqas.com. Please include your laboratory reference number and the details of the update required.

ORDERING RIQAS PRODUCTS
Please ensure your purchase order for each cycle is placed with your local Randox representative 12 weeks prior to the month in which the cycle starts. This will ensure sufficient time to process and despatch your kit(s) to you. Participants from UK or Ireland may order products directly from RIQAS with an official order number. Orders received within 12 weeks of the start of the cycle will be processed with an additional administration fee. Current prices of RIQAS products are available from your local Randox Laboratories representative.

It may be possible to order RIQAS products during a cycle, subject to availability. Please contact your local Randox representative for more information.

SHIPPING AND RECEIPT OF RIQAS PRODUCTS
Provided that you have ordered sufficiently in advance, your RIQASkit(s) will be shipped to you to arrive before the analysis date of the first sample in the kit. If you do not receive your kit(s) before this time, please contact your local Randox representative.

On RIQASNet please access your account and download the relevant Instructions For Use (IFU) document for the programme and cycle purchased. The IFU includes material characteristics, preparation, stability, storage and safety information. On receipt of your RIQAS kit, please check that:

- It is the product you ordered.
- The correct number of samples are present as indicated on the IFU.
- The samples have the appearance as indicated on the IFU and that none of them are damaged.

Please notify your local Randox representative immediately if any of these are incorrect.

Please ensure that the product is immediately stored according to the recommendations on the package labelling.

ASSAY OF SAMPLES & RETURN OF RESULTS
Carefully read the instructions stated on the Instructions for Use (IFU) prior to preparation and assay of RIQAS samples. These are available on RIQASNet only. The RIQAS samples should be assayed at the recommended time specified on the IFU. Following appropriate preparation, samples should be treated as routine, unless otherwise stated on the IFU. Please assay the samples on or before the recommended date for analysis and forward your results to RIQAS by no later than 17:00 GMT on the FINAL DATE, as indicated in the IFU. Results are submitted via RIQASNet, which can be accessed once you have received log in details via email. This will include a link to RIQASNet Instructions for Use.

Case studies are provided for each sample. These can also be downloaded from RiqasNet.

LATE AND CORRECTED RESULTS
In keeping with the objectives of EQA schemes, participants should be aware that collusion and falsification of results is considered to be unethical and constitutes scientific fraud. RIQAS policies must ensure that a laboratory is unaware of RIQAS means for comparison before submitting their own results. Where a result is not submitted by the final date, a report will be issued, but the missing results will be indicated as “No return” or “N” throughout the RIQAS reports. RIQAS permits the submission of late or corrected results only under the circumstances described below. Requests for the submission of late or corrected results must be submitted in writing and in English on RIQAS Form No. 9277-RQ (either by the participant or their local Randox Representative) and must be approved by RIQAS Management. The form is available on www.riqas.net.

Requests for the submission of late results must be accompanied by evidence that an error has been made, and that the error has not been caused by the participant.

Requests for the correction or removal of erroneous results must be accompanied by evidence that the error was non-analytical, as defined on form 9277-RQ. RIQAS is obliged to inform country-specific regulatory bodies of requests for correction of results (if they request such information for laboratory monitoring purposes).

New reports will be re-issued for late or corrected results only where there has been an error made by Randox Laboratories HQ, Randox representatives or distributors.

LATE RESULTS
In general, late results will not be accepted after the final date.

Late results will only be accepted where there has been an error made by Randox Laboratories HQ, Randox representatives or distributors.

CORRECTED RESULTS
Labs may correct results only if it can be determined that the error was non-analytical and where the request for submission is within 4 weeks of the original final date. A laboratory may correct a result under the following circumstances:

- Reconstituting a sample in an incorrect volume before analysis
- Assaying and/or submitting the results for the wrong sample
- Making a transcription error - submission of an analyser print-out indicating that the analysis date was before the final date is required.

DESPATCH OF REPORTS
PDF reports will be emailed within 72 hours of the FINAL DATE and for those registered for RIQASNet, the PDF reports will be available on RIQASNet shortly after.
USE OF RIQAS REPORTS
Participants have permission to make copies of their RIQAS reports for internal use and for regulatory purposes only. RIQAS reports must not be duplicated for external use without permission from the RIQAS Scheme Co-ordinator. Under no circumstances should information on RIQAS reports be taken out of context or falsified in any way. Information regarding the format of RIQAS Reports and the monitoring of EQA performance can be found in the RIQAS Brochure at www.randox.com/external-quality-assessment

CONFIDENTIALITY
Participation in any RIQAS programme is considered to be strictly confidential. Any data transfer or correspondence with participants, either directly or via local Randox representative, will be deemed confidential. Participants should be aware that regulatory authorities have the right to request an assessment of a participant's performance. Where regulatory authorities are to be provided with a participant's results, participants will be notified.

GENERAL DATA PROTECTION REGULATION 2018 & UK DATA PROTECTION ACT 2018
Randox Laboratories Ltd. complies with GDPR and the UK Data Protection Act and holds the minimum information required to maintain the contract with RIQAS customers. Contact details are required in order to effectively provide you with the RIQAS products and services. Participants are not under any obligation to provide personal information to enter into a contract with RIQAS. We recommend that business contact details are provided. All data associated with the provision of RIQAS is collated, stored and processed confidentially and securely, to avoid unlawful processing, accidental loss or damage

CERTIFICATES OF PARTICIPATION
Complimentary certificates of participation for each RIQAS programme are made available on RIQASNet to participants at the end of the current cycle, provided that at least 50% of results have been returned. Participants who enrol mid-cycle will be eligible for a Certificate for Participation if they have participated in at least 50% of samples available for the remainder of the cycle since enrolment. The certificate will specify the cycle, programme and the LABORATORY / HOSPITAL NAME which is detailed in the certificate section of RIQASNet. At the end of a cycle, a list of all eligible labs will be exported from RIQASNet and certificates will be created according to these details. Please ensure all certificate details are up to date in your RIQASNet account.

PERFORMANCE SURVEILLANCE OF UK LABS
RIQAS is obligated to identify and report persistent poor performing UK labs to the National Quality Assessment Advisory Panel. Poor performers are identified as those failing to meet performance criteria agreed with NQAAP. The performance criteria is specified in all performance surveillance correspondence with participants, and is also available on request. Participants are initially informed of poor performance by letter. Failure to improve performance will prompt details to be forwarded to NQAAP. All information sent to participants and NQAAP is strictly confidential. Please contact RIQAS if you require further information on Performance Surveillance.

PARTICIPANT FEEDBACK, COMPLAINTS & APPEALS
In order to ensure that RIQAS provides an appropriate and satisfying service, participants are invited to complete a feedback survey on RIQASNet. You may contact us at any time during the cycle, should you have any requests for additional programmes or parameters or comments regarding existing programmes. RIQAS makes every effort to ensure that the samples provided are clinically challenging to as many laboratory systems as possible. For details, please contact RIQAS either directly or through your local Randox representative. Should the need arise, participants may raise requests or enquiries through correspondence with the local Randox Laboratories representative or by contacting RIQAS directly. Participants may appeal against the evaluation of their performance by completing a PARTICIPANT APPEALS FORM, 10770-RQ. Participants may raise a complaint in relation to the product or service provided by completing the PARTICIPANT COMPLAINTS FORM, 10772-RQ. These forms are available on RIQASNet, or on request from RIQAS.

SUB-CONTRACTING
RIQAS sub-contracts aspects of the scheme. RIQAS accepts responsibility for the sub-contractors' work and protocols are in place to ensure that sub-contractors are deemed competent.

OUR COMPETENCE AS A PROFICIENCY TESTING PROVIDER
On request, RIQAS is willing to co-operate with participants seeking evidence of our competence as a proficiency testing provider or information on the design and implementation of RIQAS Programmes.

DEVIATION FROM EXISTING POLICIES/SERVICE
If there is any deviation from the existing policies or service, participants will be notified either directly or via their local Randox representative.

COMMUNICATION
As part of the service provided by Randox Laboratories Ltd., participants may be contacted by e-mail regarding updates and new products, in line with Randox Laboratories Ltd. privacy policy, as stated in www.randox.com.

Please contact RIQAS at
Tel: +44 (0) 28 9445 4399
E-Mail mail@riqas.com
RIQAS Scheme Co-ordinator: Sally Picton
RANDOX LABORATORIES LTD., 55 Diamond Road, Crumlin, County Antrim, BT29 4QY, United Kingdom
**RQ9197 - MICROBIOLOGY - Bacterial Identification**

**METHOD QUESTIONNAIRE**

**Bacterial Identification**

**METHOD**

- Alifax HB&L
- Alifax Sidecar
- Autoscan 4
- BD Phoenix (all models)
- Biomerieux BACT/ALERT
- Biomerieux Biofire
- BioRad Adagio
- Conventional Tests
- DNA Sequencing
- MALDI-ToF
- Microflex LT/SH
- MicroScan WalkAway
- Sensititre Aris 2X
- VITEK 2 (all models)
- VITEK MS

Other methods, please specify on enrolment document

**Guidelines (antimicrobial susceptibility testing standards)**

- BSAC
- CA-SFM
- CLSI
- EUCAST
- NWGA

Other Guidelines, please specify on enrolment document

**Antibiotics**

- **Amikacin**
- **Ciprofloxacin**
- **Mycifergen**
- **Ampicillin**
- **Clarithromycin**
- **Miconazole**
- **Augmentin**
- **Clindamycin**
- **Minocycline**
- **Azithromycin**
- **Clotrimazole**
- **Moxifloxacin**
- **Aztreonam**
- **Clodecycline**
- **Nystatin**
- **Benzylpenicillin**
- **Econazole**
- **Oxacillin**
- **Casopfungin**
- **Enrofloxacin**
- **Penicillin**
- **Cefaclor**
- **Ertapenem**
- **Piperacillin**
- **Cefazolin**
- **Erythromycin**
- **Piperacillin Tazobactam**
- **Cefepime**
- **Flucloxacillin**
- **Piperacillin Tazobactam**
- **Cefotaxime**
- **Flucnozole**
- **Polimixin B**
- **Cefodime**
- **Flucytosin**
- **Quinupristin/Dalopristin**
- **Cefoperazone**
- **Fosfomycin**
- **Rifampcin**
- **Cefotaxime/Sulbactam**
- **Fusidic Acid**
- **Spectinomycin**
- **Ceftriaxone**
- **Gentamicin**
- **Streptomycin**
- **Cefuroxime**
- **Gentamicin High Level**
- **Streptomycin High Level**
- **Ceftriaxone**
- **Levofluoxacin**
- **Ticarcillin**
- **Ceftazidime**
- **Linezolid**
- **Tigecycline**
- **Ceftriaxone**
- **Metopenem**
- **Tobramycin**
- **Cefzeugox**
- **Methicillin**
- **Trimethoprim/Sulfamethoxazole**
- **Ceftriaxone**
- **Meropenem**
- **Vancomycin**
- **Cephalothin**
- **Metoxazole**
- **Voriconazole**
- **Chloramphenicol**
- **Metoxazole**
- **Voriconazole**

If additional antibiotics would be routinely used, please specify on enrolment document

RQ9197 Method Questionnaire 5/6

Revised Nov 2023
<table>
<thead>
<tr>
<th>Microorganism</th>
<th>Microorganism</th>
<th>Microorganism</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alicyclobacillus</td>
<td>Enterobacter ludwigii</td>
<td>Enterobacter sakazakii</td>
</tr>
<tr>
<td>Alicyclobacillus acidocaldarius</td>
<td>Enterobacter nimipressuralis</td>
<td>Enterococcus casseliflavus</td>
</tr>
<tr>
<td>Bacteroides</td>
<td>Bacteroides bivius</td>
<td>Enterococcus faecalis</td>
</tr>
<tr>
<td>Bacteroides distasonis</td>
<td>Bacteroides fragilis</td>
<td>Enterococcus faecium</td>
</tr>
<tr>
<td>Bacteroides fragilis group</td>
<td>Bacteroides ovatus</td>
<td>Enterococcus gallinarum</td>
</tr>
<tr>
<td>Bacteroides splanchicus</td>
<td>Bacteroides thetaiotaomicron</td>
<td>Enterococcus hirae</td>
</tr>
<tr>
<td>Bacteroides ureolyticus</td>
<td>Bacteroides vulgatus</td>
<td>Enterococcus raffinosus</td>
</tr>
<tr>
<td>Campylobacter</td>
<td>Campylobacter coli</td>
<td>Escherichia coli</td>
</tr>
<tr>
<td>Campylobacter fetus</td>
<td>Campylobacter jejuni</td>
<td>Escherichia coli (0103:H11)</td>
</tr>
<tr>
<td>Candida</td>
<td>Candida albicans</td>
<td>Escherichia coli (0111:H8)</td>
</tr>
<tr>
<td>Candida auris</td>
<td>Candida dubliniensis</td>
<td>Escherichia coli (0121:H19)</td>
</tr>
<tr>
<td>Candida glabrata</td>
<td>Candida nivariensis</td>
<td>Escherichia coli (0145:NM)</td>
</tr>
<tr>
<td>Candida parapsilosis</td>
<td>Citrobacter</td>
<td>Escherichia coli (0157:H7)</td>
</tr>
<tr>
<td>Citrobacter</td>
<td>Citrobacter amalonaticus</td>
<td>Escherichia coli (026:H11)</td>
</tr>
<tr>
<td>Citrobacter braakii</td>
<td>Citrobacter freundii</td>
<td>Escherichia coli (045:H2)</td>
</tr>
<tr>
<td>Citrobacter koseri</td>
<td>Clostridioides</td>
<td>Haemophilus</td>
</tr>
<tr>
<td>Clostridioides</td>
<td>Clostridioides difficile</td>
<td>Haemophilus influenzae</td>
</tr>
<tr>
<td>Clostridium</td>
<td>Clostridium bifermentans</td>
<td>Haemophilus parainfluenzae</td>
</tr>
<tr>
<td>Clostridium bifermentans</td>
<td>Clostridium clostridiiforme</td>
<td>Klebsiella aerogenes</td>
</tr>
<tr>
<td>Clostridium histolyticum</td>
<td>Clostridium innocuum</td>
<td>Klebsiella oxytica</td>
</tr>
<tr>
<td>Clostridium novyi</td>
<td>Clostridium perfringens</td>
<td>Klebsiella ozaeae</td>
</tr>
<tr>
<td>Clostridium perfringens</td>
<td>Clostridium ramosum</td>
<td>Klebsiella pneumoniae</td>
</tr>
<tr>
<td>Clostridium ramsonum</td>
<td>Clostridium septicum</td>
<td>Listeria</td>
</tr>
<tr>
<td>Clostridium septicum</td>
<td>Clostridium sordellii</td>
<td>Listeria innocua</td>
</tr>
<tr>
<td>Clostridium sporogenes</td>
<td>Clostridium sporogenes</td>
<td>Listeria monocytogenes</td>
</tr>
<tr>
<td>Clostridium tertium</td>
<td>Clostridium tertium</td>
<td>Moraxella</td>
</tr>
<tr>
<td>Clostridium tetani</td>
<td>Enterobacter</td>
<td>Moraxella catarrhalis</td>
</tr>
<tr>
<td>Enterobacter agglomerans</td>
<td>Enterobacter asburiae</td>
<td>Neisseria</td>
</tr>
<tr>
<td>Enterobacter asburiae</td>
<td>Enterobacter cloacae</td>
<td>Neisseria gonorrhoeae</td>
</tr>
<tr>
<td>Enterobacter cloacae</td>
<td>Enterobacter gergoviae</td>
<td>Neisseria lactamica</td>
</tr>
<tr>
<td>Enterobacter gergoviae</td>
<td>Enterobacter hormaechei</td>
<td>Neisseria meningitidis</td>
</tr>
<tr>
<td>Enterobacter hormaechei</td>
<td>Enterobacter kobei</td>
<td>Neisseria subflava</td>
</tr>
<tr>
<td>Enterobacter kobei</td>
<td>Salmonella</td>
<td>Proteus</td>
</tr>
<tr>
<td>Salmonella</td>
<td>Salmonella enterica</td>
<td>Proteus mirabilis</td>
</tr>
<tr>
<td>Streptococcus</td>
<td>Streptococcus agalactiae</td>
<td>Proteus penneri</td>
</tr>
<tr>
<td>Streptococcus</td>
<td>Streptococcus alactolyticus</td>
<td>Proteus vulgaris</td>
</tr>
<tr>
<td>Streptococcus</td>
<td>Streptococcus anginosus</td>
<td>Pseudomonas aeruginosa</td>
</tr>
<tr>
<td>Streptococcus</td>
<td>Streptococcus bovis</td>
<td>Pseudomonas fluorescens</td>
</tr>
<tr>
<td>Streptococcus</td>
<td>Streptococcus equinus</td>
<td>Pseudomonas putida</td>
</tr>
<tr>
<td>Streptococcus</td>
<td>Streptococcus galloyticus</td>
<td>Pseudomonas stutzeri</td>
</tr>
<tr>
<td>Streptococcus</td>
<td>Streptococcus infantarius</td>
<td>Saccharomyces</td>
</tr>
<tr>
<td>Streptococcus interpemedius</td>
<td>Streptococcus mitis</td>
<td>Saccharomyces cerevisiae</td>
</tr>
<tr>
<td>Streptococcus</td>
<td>Streptococcus pneumonia</td>
<td>Salmonella</td>
</tr>
<tr>
<td>Streptococcus</td>
<td>Streptococcus pyogenes</td>
<td>Salmonella enterica</td>
</tr>
<tr>
<td>Streptococcus</td>
<td>Vibrio</td>
<td>Vibrio</td>
</tr>
<tr>
<td>Streptococcus</td>
<td>Vibrio alginolyticus</td>
<td>Vibrio</td>
</tr>
<tr>
<td>Streptococcus</td>
<td>Vibrio cholerae</td>
<td>Vibrio</td>
</tr>
<tr>
<td>Streptococcus</td>
<td>Vibrio cincinnatiensis</td>
<td>Vibrio</td>
</tr>
<tr>
<td>Streptococcus</td>
<td>Vibrio fluvialis</td>
<td>Vibrio</td>
</tr>
<tr>
<td>Streptococcus</td>
<td>Vibrio furnissi</td>
<td>Vibrio</td>
</tr>
<tr>
<td>Streptococcus</td>
<td>Vibrio harveyi</td>
<td>Vibrio</td>
</tr>
<tr>
<td>Streptococcus</td>
<td>Vibrio metchnikovii</td>
<td>Vibrio</td>
</tr>
<tr>
<td>Streptococcus</td>
<td>Vibrio mimicus</td>
<td>Vibrio</td>
</tr>
<tr>
<td>Streptococcus</td>
<td>Vibrio paraahemolyticus</td>
<td>Vibrio</td>
</tr>
<tr>
<td>Streptococcus</td>
<td>Vibrio vulnificus</td>
<td>Vibrio</td>
</tr>
<tr>
<td>Streptococcus</td>
<td>Zygosaccharomyces</td>
<td>Zygosaccharomyces rouxii</td>
</tr>
</tbody>
</table>